← Oncology Approval Tracker

FDA DECISION ·

Keytruda + chemotherapy

pembrolizumab + chemotherapy · Merck Sharp & Dohme

Accelerated approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Jul 26, 2021

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Locally recurrent unresectable or metastatic triple-negative breast cancer with PD-L1 combined positive score of at least 10 on an FDA-approved test, in combination with chemotherapy.

LAMPGEN ANALYSIS

Why it matters

Added a checkpoint inhibitor to chemotherapy for a PD-L1-selected advanced TNBC population under accelerated approval.

What research teams should watch

Capture the combined positive score and chosen chemotherapy regimen and distinguish immune from chemotherapy toxicities.

PRIMARY RECORDS

Sources